Emerging therapeutic concepts for muscle and bone preservation/formation

Compston, JE; Fearon, Kenneth C. H.

doi:10.1016/j.bone.2015.08.011

Cited by 2 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical relevance of anabolic agents is undisputed, especially in cases of hormone deficiency and in light of the fact that the entity of skeletal muscle of a human being accounts for approximately 40% of the total body mass representing a major metabolic and essential organ. Further, the functionality of muscles associated with respiration is vital, and clinical situations such as severe cachexia necessitate therapeutic interventions based on anabolic agents . However, the enormous breadth of yet inevitable undesirable effects of anabolic agents, particularly anabolic‐androgenic steroids (AAS), continuously results in reports on risks, documented health damages, and fatalities plausibly connected to (long‐term) AAS abuse.…”

Section: Anabolic Agentsmentioning

confidence: 99%

“…Further, the functionality of muscles associated with respiration is vital, and clinical situations such as severe cachexia necessitate therapeutic interventions based on anabolic agents. [36] However, the enormous breadth of yet inevitable undesirable effects of anabolic agents, particularly anabolic-androgenic steroids (AAS), continuously results in reports on risks, [37][38][39][40][41][42][43][44][45][46] documented health damages, [47][48][49][50][51][52][53][54] and fatalities [55] plausibly connected to (long-term) AAS abuse. Despite this steadily growing body of evidence concerning AASrelated adverse health effects, the class of anabolic agents (in particular AAS) has again been most frequently reported with regard to adverse analytical findings in doping control samples.…”

Section: Anabolic-androgenic Steroidsmentioning

confidence: 99%

“…Alternatives to AAS in therapies concerning cachexia have been of particular interest for many years. A variety of drug candidates has emerged since, among which the class of selective androgen receptor modulators (SARMs) has played a major role [36] warranting a continuous update of test methods for these agents. Knoop et al studied the phase I and phase II metabolic reactions of LG121071, a tetrahydroquinolinone-derived SARM, by means of human liver microsomal preparations.…”

Section: Other Anabolic Agentsmentioning

confidence: 99%

“…Besides the commonly collected specimens of urine, serum, and whole blood, a growing interest in alternative test matrices such [27][28][29]31,33,35] S1 Anabolic Agents 1 Anabolic androgenic steroids [36][37][38][39][43][44][45][46][47][48][49][50][51][52][53][54][55][56] a. exogenous [63][64][65]67,69,70] 2 Other anabolic agents - [85,86,92,93] - [60,[87][88][89][90][91][92] S2 Peptide hormones, growth factors, related substances and mimetics 1 Erythropoiesis-Stimulating Agents [119] [ 27,33,105,106,112] - [24,27,…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Annual banned‐substance review: analytical approaches in human sports drug testing

Thevis

Kuuranne

Walpurgis

et al. 2016

Drug Testing and Analysis

View full text Add to dashboard Cite

The aim of improving anti-doping efforts is predicated on several different pillars, including, amongst others, optimized analytical methods. These commonly result from exploiting most recent developments in analytical instrumentation as well as research data on elite athletes' physiology in general, and pharmacology, metabolism, elimination, and downstream effects of prohibited substances and methods of doping, in particular. The need for frequent and adequate adaptations of sports drug testing procedures has been incessant, largely due to the uninterrupted emergence of new chemical entities but also due to the apparent use of established or even obsolete drugs for reasons other than therapeutic means, such as assumed beneficial effects on endurance, strength, and regeneration capacities. Continuing the series of annual banned-substance reviews, literature concerning human sports drug testing published between October 2014 and September 2015 is summarized and reviewed in reference to the content of the 2015 Prohibited List as issued by the World Anti-Doping Agency (WADA), with particular emphasis on analytical approaches and their contribution to enhanced doping controls.

show abstract

Section: Anabolic Agentsmentioning

confidence: 99%

Section: Anabolic-androgenic Steroidsmentioning

confidence: 99%

Section: Other Anabolic Agentsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Annual banned‐substance review: analytical approaches in human sports drug testing

Thevis

Kuuranne

Walpurgis

et al. 2016

Drug Testing and Analysis

View full text Add to dashboard Cite

show abstract

Selecting Potential Pharmacological Interventions in Sarcopenia

2017

View full text Add to dashboard Cite

Abstract:Sarcopenia of age is prevalent, costly, but currently lacks proven pharmacological interventions. The pathophysiology of sarcopenia is incompletely understood, but appears to involve multiple pathways including inflammation, hormonal dysregulation, impaired regeneration, mitochondrial dysfunction and denervation. There are several ways that we might select potential pharmacological interventions for testing in clinical trials. These include a 'bottom up' approach using basic science to elucidate the molecular processes involved and identifying potential targets from this knowledge -a strategy that has led to the development of myostatin inhibitors. A 'top down' approach might use observational data to examine the association between physical function and use of certain medications, such as the association of angiotensin converting enzyme inhibitors with slower decline in physical function.. Once a pharmacological intervention has been proposed, efficacy must be demonstrated in this complex multi-morbid population. Both muscle mass and muscle function need to be measured as outcomes, but these outcomes require large sample sizes and sufficient follow-up to detect change. 2Biomarkers that can predict the response of sarcopenia to intervention after a short time would greatly assist our ability to select candidate interventions in short proof of concept trials. Further development of trial methods is required to accelerate progress in this important area of medicine for older people.

show abstract

Emerging therapeutic concepts for muscle and bone preservation/formation

Cited by 2 publications

References 46 publications

Annual banned‐substance review: analytical approaches in human sports drug testing

Annual banned‐substance review: analytical approaches in human sports drug testing

Selecting Potential Pharmacological Interventions in Sarcopenia

Contact Info

Product

Resources

About